Search global stocks & ETFs...Ctrl K

Learn Mode

AUPH - Aurinia Pharmaceuticals Inc

17

$15.28

-$0.56 (-3.535%)

At market close

$15.21

-$0.07 (-0.452%)

After Hours 5/15/26, 11:37 PM

Score

4.35/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

AUPH

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.97B

Industry

Biotechnology

EPS (TTM)

$2.17

P/E (TTM)

6.59

Div & Yield

FCF Payout Ratio

P/S (TTM)

6.59

P/B

3.46

Diluted Shares

137.64M

Ex-Dividend

Next Earnings

07-29

Forward P/E

16.52

Payout Ratio

P/FCF (TTM)

11.79

FCF Yield

8.48%

Earnings Yield

15.18%

52 Week Range

Score Card

Explore Scores Tab

4.35

Very Good

Aurinia Pharmaceuticals Inc has grown revenue at 20.62% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

1.00

Very Bad

Growth

5.00

Very Good

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

5 new filings were in the last 7 days

Filter Form Types

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-11 16:11:24

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-11 16:10:02

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-11 16:07:37

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-11 09:20:50

Form SC TO-T/A

Unknown Form Type

Filed on 2026-05-11 09:15:20

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-07 08:23:35

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 08:22:07

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-21 16:31:08

Form SC TO-T

Unknown Form Type

Filed on 2026-04-13 07:27:23

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-03 16:56:49

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:19:38

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:19:18

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$22.05

44.3%

Avg:

$17.34

13.5%

Low:

$15.15

-0.9%

(% change is relative to the current stock price: $15.28)

Analyst Recommendations

Go to Analyst Tab

3.92

Good

23%

Strong Buy (3)

46%

Buy (6)

31%

Hold (4)

Sell (0)

Strong Sell (0)

About

Website
https://www.auriniapharma.com
Address
Suite 1203-4464 Markham Street, Edmonton BRITISH COLUMBIA, CA
SEC Reports
https://sec.gov/edgar/browse/?CIK=1600620

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

IPO Date

2001-07-16

Industry

Biotechnology

Total Employees

300

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

AUPH - Aurinia Pharmaceuticals Inc

17

$15.28

-$0.56 (-3.535%)

$15.21

-$0.07 (-0.452%)

4.35/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form 144

Filed on 2026-05-11 16:11:24

Form 144

Filed on 2026-05-11 16:10:02

Form 144

Filed on 2026-05-11 16:07:37

Form 8-K

Filed on 2026-05-11 09:20:50

Form SC TO-T/A

Filed on 2026-05-11 09:15:20

Form 10-Q

Filed on 2026-05-07 08:23:35

Form 8-K

Filed on 2026-05-07 08:22:07

Form DEF 14A

Filed on 2026-04-21 16:31:08

Form SC TO-T

Filed on 2026-04-13 07:27:23

Form 8-K

Filed on 2026-04-03 16:56:49

Form 3

Filed on 2026-04-02 16:19:38

Form 3

Filed on 2026-04-02 16:19:18

Financials

Price Targets

44.3%

13.5%

-0.9%

Analyst Recommendations

About

Similar Stocks